QIAGEN Buys Diagnostics Firm
QIAGEN told IBO that PrimeraDx has 30 employees but declined to disclose the acquisition date. Formerly known as ICEPlex, the PrimeraDx platform utilizes PCR-based multiplex reactions and capillary electrophoresis. PrimeraDx entered into a multiyear, companion-diagnostics partnership with Eli Lilly in 2012.
Hilden, Germany and Germantown, MD 5/30/14—QIAGEN disclosed as part of an announcement of a codevelopment deal with Eli Lilly and Company for companion diagnostics, that it has acquired PrimeraDx. All PrimeraDx employees have joined QIAGEN. PrimeraDx’s multimodal, multianalyte platform enables the simultaneous single-assay analysis of dozens of DNA and RNA biomarkers, their copy numbers, expression levels and mutations. Under the Eli Lilly agreement, the platform, now known as Modaplex, will be used to develop tests for multiple biomarkers for cellular pathways associated with cancer therapeutics. This is QIAGEN’s fourth project with Eli Lilly.
